StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Metagenomi Therapeutics's profit margin for the twelve months ending Mar 31, 2026 was -384.6%. For fiscal 2025 it was -348.5%, against -149.3% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-348.5%−199.3
FY2024Dec 31, 2024-149.3%+3.2
FY2023Dec 31, 2023-152.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-1847.7%−1241.0
Q4 FY2025Dec 31, 2025-576.0%−332.6
Q3 FY2025Sep 30, 2025-235.5%−72.5
Q2 FY2025Jun 30, 2025-233.9%−180.2
Q1 FY2025Mar 31, 2025-606.7%−381.4
Q4 FY2024Dec 31, 2024-243.4%−87.8
Q3 FY2024Sep 30, 2024-163.0%−2.7
Q2 FY2024Jun 30, 2024-53.7%+61.1
Q1 FY2024Mar 31, 2024-225.4%−39.0
Q4 FY2023Dec 31, 2023-155.6%–
Q3 FY2023Sep 30, 2023-160.3%–
Q2 FY2023Jun 30, 2023-114.7%–
Q1 FY2023Mar 31, 2023-186.4%–

More Metagenomi Therapeutics figures

See a number that looks wrong?